Calmodulin-binding sites on target proteins show considerable variation in
primary sequence; hence compounds that block the access of calmodulin to th
ese binding sites may be more selective than compounds that inactivate, cal
modulin. Suramin and its analogue NF307 inhibit the interaction of calmodul
in with the ryanodine receptor. We have investigated whether inhibition of
calmodulin binding to target proteins is a general property of these compou
nds. Suramin inhibited binding of [I-125]calmodulin to porcine brain membra
nes and to sarcoplasmic reticulum from skeletal muscle (IC50 = 4.9 +/- 1.2
muM and 19.9 +/- 1.8 muM, respectively) and blocked the cross-linking of [I
-125]calmodulin to some, but not ail, target proteins in brain membranes by
[I-125]calmodulin. Four calmodulin-binding proteins were purified [ryanodi
ne receptor-1 (RyR1) from rabbit skeletal muscle, neuronal NO synthase (nNO
S) from Sf9 cells, G-protein beta gamma dimers (G beta gamma) from porcine
brain and a glutathione S-transferase-fusion protein comprising the C-termi
nal calmodulin-binding domain of the metabotropic glutamate receptor 7A (GS
T-CmGluR7A) from bacterial lysates]. Three of the proteins employed (G beta
gamma, GST-CmGluR7A and RyR1) display a comparable affinity for calmodulin
(in the range of 50-70 nM). Nevertheless, suramin and NF307 only blocked t
he binding of G beta gamma and RyR1 to calmodulin-Sepharose. In contrast, t
he association of GST-CmGluR7A and nNOS was not impaired, whereas excess ca
lmodulin uniformly displaced all proteins from the matrix. Thus suramin and
NF307 are prototypes of a new class of calmodulin antagonists that do not
interact directly with calmodulin but with calmodulin-recognition sites. In
addition, these compounds discriminate among calmodulin-binding motifs.